Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: A randomized controlled trial

Alessandra Mangia, Maria Rosaria Villani, Nicola Minerva, Gioacchino Leandro, Donato Bacca, Marina Cela, Vito Carretta, Vito Attino, Francesco Ventrella, Antonio Giangaspero, Angelo Andriulli

Research output: Contribution to journalArticle

Abstract

Background: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Aims: To compare the efficacy of 5 MU tiw of IFN with (96 patients) or without ribavirin (96 patients) for 12 months in naive patients, to evaluate the effect of baseline features on the response to therapy, and to determine a reliable point in time during treatment to predict non-response. Results: Sustained virologic response was 20.8% (95% CI 13-29) with IFN monotherapy and 54.2% (95% CI 44-64) with combination (P = 0.0001), the relapse rate 39.4% (95% CI 23-56) and 9% (95% CI 1-16) (P = 0.0007), and the combined rate of sustained biochemical and virologic response 22.7% (95% CI 14-31) and 60.5% (95% CI 50-71) (P = 0.0001), respectively. Patients given combination therapy were more likely to respond regardless of baseline features. Apart from genotype non-1, predictive factors for IFN monotherapy were ineffective in predicting response to combination therapy. Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (Χ2 = 21.3; P = 0.0001). Viral persistence at month 3 of therapy was a more accurate predictor than aminotransferase values for non-response to IFN monotherapy but not to combination therapy (positive predictive values of 98 and 82%, respectively). Conclusion: In this study, 5 MU of IFN combined with a standard dose of ribavirin has yielded the highest rate of sustained response reported to date. Further dose finding studies are warranted.

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalJournal of Hepatology
Volume34
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepacivirus
Interferons
Randomized Controlled Trials
Therapeutics
Transaminases
Appointments and Schedules
Logistic Models
Genotype
Regression Analysis
Recurrence

Keywords

  • Chronic liver disease
  • Hepatitis C virus
  • Interferon α
  • Randomized clinical trial
  • Ribavirin
  • Viral hepatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus : A randomized controlled trial. / Mangia, Alessandra; Villani, Maria Rosaria; Minerva, Nicola; Leandro, Gioacchino; Bacca, Donato; Cela, Marina; Carretta, Vito; Attino, Vito; Ventrella, Francesco; Giangaspero, Antonio; Andriulli, Angelo.

In: Journal of Hepatology, Vol. 34, No. 3, 2001, p. 441-446.

Research output: Contribution to journalArticle

Mangia, Alessandra ; Villani, Maria Rosaria ; Minerva, Nicola ; Leandro, Gioacchino ; Bacca, Donato ; Cela, Marina ; Carretta, Vito ; Attino, Vito ; Ventrella, Francesco ; Giangaspero, Antonio ; Andriulli, Angelo. / Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus : A randomized controlled trial. In: Journal of Hepatology. 2001 ; Vol. 34, No. 3. pp. 441-446.
@article{fdfb32aaa0c04155853c2075a2515503,
title = "Efficacy of 5 MU of interferon in combination with ribavirin for na{\"i}ve patients with chronic hepatitis C virus: A randomized controlled trial",
abstract = "Background: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Aims: To compare the efficacy of 5 MU tiw of IFN with (96 patients) or without ribavirin (96 patients) for 12 months in naive patients, to evaluate the effect of baseline features on the response to therapy, and to determine a reliable point in time during treatment to predict non-response. Results: Sustained virologic response was 20.8{\%} (95{\%} CI 13-29) with IFN monotherapy and 54.2{\%} (95{\%} CI 44-64) with combination (P = 0.0001), the relapse rate 39.4{\%} (95{\%} CI 23-56) and 9{\%} (95{\%} CI 1-16) (P = 0.0007), and the combined rate of sustained biochemical and virologic response 22.7{\%} (95{\%} CI 14-31) and 60.5{\%} (95{\%} CI 50-71) (P = 0.0001), respectively. Patients given combination therapy were more likely to respond regardless of baseline features. Apart from genotype non-1, predictive factors for IFN monotherapy were ineffective in predicting response to combination therapy. Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (Χ2 = 21.3; P = 0.0001). Viral persistence at month 3 of therapy was a more accurate predictor than aminotransferase values for non-response to IFN monotherapy but not to combination therapy (positive predictive values of 98 and 82{\%}, respectively). Conclusion: In this study, 5 MU of IFN combined with a standard dose of ribavirin has yielded the highest rate of sustained response reported to date. Further dose finding studies are warranted.",
keywords = "Chronic liver disease, Hepatitis C virus, Interferon α, Randomized clinical trial, Ribavirin, Viral hepatitis",
author = "Alessandra Mangia and Villani, {Maria Rosaria} and Nicola Minerva and Gioacchino Leandro and Donato Bacca and Marina Cela and Vito Carretta and Vito Attino and Francesco Ventrella and Antonio Giangaspero and Angelo Andriulli",
year = "2001",
doi = "10.1016/S0168-8278(00)00024-6",
language = "English",
volume = "34",
pages = "441--446",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus

T2 - A randomized controlled trial

AU - Mangia, Alessandra

AU - Villani, Maria Rosaria

AU - Minerva, Nicola

AU - Leandro, Gioacchino

AU - Bacca, Donato

AU - Cela, Marina

AU - Carretta, Vito

AU - Attino, Vito

AU - Ventrella, Francesco

AU - Giangaspero, Antonio

AU - Andriulli, Angelo

PY - 2001

Y1 - 2001

N2 - Background: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Aims: To compare the efficacy of 5 MU tiw of IFN with (96 patients) or without ribavirin (96 patients) for 12 months in naive patients, to evaluate the effect of baseline features on the response to therapy, and to determine a reliable point in time during treatment to predict non-response. Results: Sustained virologic response was 20.8% (95% CI 13-29) with IFN monotherapy and 54.2% (95% CI 44-64) with combination (P = 0.0001), the relapse rate 39.4% (95% CI 23-56) and 9% (95% CI 1-16) (P = 0.0007), and the combined rate of sustained biochemical and virologic response 22.7% (95% CI 14-31) and 60.5% (95% CI 50-71) (P = 0.0001), respectively. Patients given combination therapy were more likely to respond regardless of baseline features. Apart from genotype non-1, predictive factors for IFN monotherapy were ineffective in predicting response to combination therapy. Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (Χ2 = 21.3; P = 0.0001). Viral persistence at month 3 of therapy was a more accurate predictor than aminotransferase values for non-response to IFN monotherapy but not to combination therapy (positive predictive values of 98 and 82%, respectively). Conclusion: In this study, 5 MU of IFN combined with a standard dose of ribavirin has yielded the highest rate of sustained response reported to date. Further dose finding studies are warranted.

AB - Background: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Aims: To compare the efficacy of 5 MU tiw of IFN with (96 patients) or without ribavirin (96 patients) for 12 months in naive patients, to evaluate the effect of baseline features on the response to therapy, and to determine a reliable point in time during treatment to predict non-response. Results: Sustained virologic response was 20.8% (95% CI 13-29) with IFN monotherapy and 54.2% (95% CI 44-64) with combination (P = 0.0001), the relapse rate 39.4% (95% CI 23-56) and 9% (95% CI 1-16) (P = 0.0007), and the combined rate of sustained biochemical and virologic response 22.7% (95% CI 14-31) and 60.5% (95% CI 50-71) (P = 0.0001), respectively. Patients given combination therapy were more likely to respond regardless of baseline features. Apart from genotype non-1, predictive factors for IFN monotherapy were ineffective in predicting response to combination therapy. Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (Χ2 = 21.3; P = 0.0001). Viral persistence at month 3 of therapy was a more accurate predictor than aminotransferase values for non-response to IFN monotherapy but not to combination therapy (positive predictive values of 98 and 82%, respectively). Conclusion: In this study, 5 MU of IFN combined with a standard dose of ribavirin has yielded the highest rate of sustained response reported to date. Further dose finding studies are warranted.

KW - Chronic liver disease

KW - Hepatitis C virus

KW - Interferon α

KW - Randomized clinical trial

KW - Ribavirin

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=0035071635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035071635&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(00)00024-6

DO - 10.1016/S0168-8278(00)00024-6

M3 - Article

C2 - 11322207

AN - SCOPUS:0035071635

VL - 34

SP - 441

EP - 446

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -